B
B. Rive
Researcher at Lundbeck
Publications - 29
Citations - 588
B. Rive is an academic researcher from Lundbeck. The author has contributed to research in topics: Major depressive disorder & Vortioxetine. The author has an hindex of 13, co-authored 26 publications receiving 462 citations. Previous affiliations of B. Rive include Janssen Pharmaceutica.
Papers
More filters
Journal ArticleDOI
Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.
Lene Hammer-Helmich,Josep Maria Haro,Bengt Jönsson,Audrey Tanguy Melac,Sylvie Di Nicola,J. Chollet,Dominique Milea,B. Rive,D. Saragoussi +8 more
TL;DR: The greatest improvement in depressive symptoms, perceived cognitive symptoms, and functional impairment was seen immediately following initiation or switch of antidepressant therapy, followed by more gradual improvement and long-term stabilization.
Journal ArticleDOI
Comparison of escitalopram and citalopram efficacy: A meta-analysis
TL;DR: Escitalopram was shown to be an effective therapeutic treatment for MDD, presenting significant advantages over citaloprams, and this superiority was further shown to increase with degree of severity of the depression.
Journal ArticleDOI
Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
D. Saragoussi,Michael Cronquist Christensen,Lene Hammer-Helmich,B. Rive,Maëlys Touya,Josep Maria Haro +5 more
TL;DR: The importance of recognizing and managing residual symptoms in patients with MDD, including the cognitive symptoms, to restore long-term psychosocial functioning is highlighted, and both depression severity and cognitive symptoms are associated with poor HRQoL.
Journal ArticleDOI
Psychometric Validation of Perceived Deficits Questionnaire – Depression (PDQ-D) in Patients with Major Depressive Disorder (MDD)
Journal ArticleDOI
Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease : a markov model in Finland.
TL;DR: According to the model, over 5 years the additional drug costs of treating patients with moderately severe to severe Alzheimer’s disease with memantine were amply offset by cost savings related chiefly to increased independence and delayed institutionalisation.